Antihistamines for Postacute Sequelae of SARS-CoV-2 Infection

 Melissa D.PintoNatalieLambertCharles A.DownsHeatherAbrahimThomas D.HughesAmir M.RahmaniCandace W.BurtonRanaChakraborty

DOI: https://doi.org/10.1016/j.nurpra.2021.12.016

PDF: https://www.sciencedirect.com/science/article/pii/S155541552100547X/pdfft?md5=617f76b6e4e2636438979b0a31ad655d&pid=1-s2.0-S155541552100547X-main.pdf

Highlights

•

Postacute sequelae of SARS-Co-V 2 infection (PASC) is a public health crisis.

•

Currently there are no treatments for PASC.

•

Two patients with PASC report rapid symptom resolution with antihistamine use.

•

Antihistamines may be a high accessible therapy for PASC.

Abstract

Postacute sequelae of SARS-CoV2 (PASC) infection is an emerging global health crisis, variably affecting millions worldwide. PASC has no established treatment. We describe 2 cases of PASC in response to opportune administration of over-the-counter antihistamines, with significant improvement in symptoms and ability to perform activities of daily living. Future studies are warranted to understand the potential role of histamine in the pathogenesis of PASC and explore the clinical benefits of antihistamines in the treatment of PASC.

https://www.sciencedirect.com/science/article/pii/S155541552100547X